Language Matters: What Supporters Say is Not Always What People with Cancer Hear
Steve Buechler produced our first LLS Community member written content. We are excited to provide this opportunity to other members of our online netw…
Topic COVID-19 COVID-19
What’s Next in Blood Cancer: Looking Ahead to 2023
We’ve come a long way and we continue to make substantial progress. The outlook for blood cancer patients is better than ever, but it’s still nowhere …
LLS and volunteers cheer California laws promoting health equity
LLS and blood cancer advocates are celebrating after our efforts helped make two bills become law in California, advancing health equity and improving…
Topic Dare to Dream Dare to Dream
How LLS and Advocates Helped Secure Landmark Health Reforms
Today, cancer patients—and others with other chronic conditions—are breathing a collective sigh of relief. After years of relentless efforts by LLS st…
FDA Approves New Option for Difficult to Treat, Rare Form of Childhood Leukemia
The Food and Drug Administration (FDA) approved azacitidine (Vidaza®) for pediatric patients 1 month and older with newly diagnosed juvenile myelomono…
More Than 5 Million New Yorkers Are Getting "In-Network" Access to Top Cancer Centers
New York’s newly-signed budget contains a key reform that could be nothing short of lifesaving for some cancer patients living in the state. National …
Topic Navigating Your Care Navigating Your Care
CAR T-Cell Therapy Approved for Initial Treatment of Relapsed Large B-Cell Lymphoma
The U.S. Food and Drug Administration (FDA) last week approved axicabtagene ciloleucel (axi-cel, Yescarta®) for patients with large B-cell lymphoma (L…
New Drug Approval Moves Us Closer To Long-Term Control of Multiple Myeloma
Just one year after the first CAR T-cell treatment was approved for multiple myeloma, the second is about to hit the market. The FDA approved ciltacab…
FDA Approves First CAR T-Immunotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia
The U.S. Food and Drug Administration (FDA) recently announced approval of brexucabtagene autoleucel (Tecartus®) as the first and only CAR T-cell trea…
Highlights from ASCO 2021
The 2021 American Society of Clinical Oncology (ASCO) Annual Meeting took place last week. ASCO brings together the cancer community to explore the la…
_dam_file_117206.jpg?crop=true&keep=n&w=400&h=320 "Thumbnail Image")
Meet The Researcher: Dr. Christopher R. Flowers
In this Q&A, we are highlighting Dr. Christopher R. Flowers, MD, chair of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center an…
Topic Dare to Dream Dare to Dream
Because You Volunteer, Your Impact Creates a Ripple Effect
At The Leukemia & Lymphoma Society (LLS), volunteers are our superheroes. Learn about the impact our volunteers help make possible in honor of Nationa…